openPR Logo
Press release

Investigation announced for Investors in shares of Ascendis Pharma A/S (NASDAQ: ASND)

04-10-2023 07:02 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Ascendis Pharma A/S (NASDAQ: ASND) shares over potential securities laws violations.

An investigation for investors in Ascendis Pharma A/S (NASDAQ: ASND) shares over potential securities laws violations.

An investigation was announced over potential securities laws violations by Ascendis Pharma A/S in connection with certain financial statements.

Investors who purchased shares of Ascendis Pharma A/S (NASDAQ: ASND), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Ascendis Pharma A/S (NASDAQ: ASND regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Denmark based Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. Ascendis Pharma A/S reported that its annual Total Revenue rose from 7.77 million EUR in 2021 to 51.17 million EUR in 2022, and that its Net Loss increased from 383.57 million EUR in 2021 to 583.19 million EUR in 2022.

On April 3, 2023, before market hours, Ascendis Pharma A/S announced that the "U.S. Food & Drug Administration ("FDA") has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company's New Drug Application ("NDA") for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter."

Shares of Ascendis Pharma A/S (NASDAQ: ASND) declined from $134.52 per share in November 11, 2022, to as low as $64.33 per share on April 3, 2023.

Those who purchased shares of Ascendis Pharma A/S (NASDAQ: ASND) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Ascendis Pharma A/S (NASDAQ: ASND) here

News-ID: 3006629 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Revance Therapeutics, Inc …
An investor, who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), filed a lawsuit over alleged violations of Federal Securities Laws by Revance Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024, and / or those who purchased anyNASDAQ: RVNC shares prior to February 2024 and continue
Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDAQ: AZN)
Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDA …
An investor, who purchased shares of AstraZeneca PLC (NASDAQ: AZN), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by AstraZeneca PLC in connection with certain allegedly false and misleading statements made between February 23, 2022 and December 17, 2024. Investors who purchased a significant amount of shares of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, have certain options and for certain
Lawsuit filed for Investors who lost money with shares of Applied Therapeutics, Inc. (NASDAQ: APLT)
Lawsuit filed for Investors who lost money with shares of Applied Therapeutics, …
An investor, who purchased shares of Applied Therapeutics, Inc. (NASDAQ: APLT), filed a lawsuit over alleged violations of Federal Securities Laws by Applied Therapeutics, Inc. Investors who purchased shares of Applied Therapeutics, Inc. (NASDAQ: APLT) have certain options and for certain investors are short and strict deadlines running. Deadline: February 18, 2025. NASDAQ: APLT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. New York based Applied
Investigation announced for Long-Term Investors in shares of WEBTOON Entertainment Inc. (NASDAQ: WBTN) over possible Wrongdoing
Investigation announced for Long-Term Investors in shares of WEBTOON Entertainme …
An investigation on behalf of current long-term investors in shares of WEBTOON Entertainment Inc. (NASDAQ: WBTN) concerning potential breaches of fiduciary duties by certain directors of WEBTOON Entertainment Inc. was announced. Investors who are current long term investors in WEBTOON Entertainment Inc. (NASDAQ: WBTN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long

All 5 Releases


More Releases for Ascendis

Achondroplasia Treatment Market Business Growth in Future Scope 2022-2028 | BioM …
Coherent Market insight has added a new research study titled "Achondroplasia Treatment Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. The "Achondroplasia Treatment Market" Research Report is an in-depth study with top-notch information on company size, current trends, drivers, outcomes, and significant market segments. The report offers useful insights into potential market growth based on input from industry experts to
Achondroplasia Treatment Market 2022-2028 Future Business Opportunities: Ascendi …
Another factual information on the Achondroplasia Treatment Market has as of late been added by CMI to its storehouse. This research report offers an inside and out examination of various perspectives, for example, market patterns, pieces of the overall industry, drivers, restrictions, and opportunities. It gives an investigative view to settle on further choices in organizations. It covers comprehensive instructive information on various key players working over the globe. The
Achondroplasia Treatment Market is expected to witness sustainable growth 2022-2 …
The exceptional Achondroplasia Treatment Market research from Coherent Market Insights is a wonderful resource that includes a detailed description of each vendor, revenue earned, and manufacturing. The report also offers details of the major prominent companies participating in the market to help understand the competition landscape of the Achondroplasia Treatment Market. The research also offers data and figures about industry trends, drivers, and major sectors. The global Achondroplasia Treatment Market analysis
Human Growth Hormone Deficiency (GHD) Drugs Market 2020 Strategic Assessment - A …
Global Human Growth Hormone Deficiency (GHD) Drugs Market Report 2020-2023 the report provides a valuable source of insightful data for business strategists and competitive analysis of Human Growth Hormone Deficiency (GHD) Drugs Market. It provides the Human Growth Hormone Deficiency (GHD) Drugs industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis.
Global Prostaglandin E2 Receptor EP2 Subtype Market 2020 - Amgen Inc. , Ascendis …
Goble Prostaglandin E2 Receptor EP2 Subtype Market 2020, Market Size Value CAGR (USD Million)and revenue ($$$) for the historical period (2016 – 19) and projected years (2020 – 26), SWOT, Industry, Sales, Demand, Analysis, Opportunities and Forecast to 2026 All Cover in This Report Prostaglandin E2 Receptor EP2 Subtype Market study on most trending report Global global Prostaglandin E2 Receptor EP2 Subtype Market 2020 Industry Research Report detailed information
Ascendis Launches Funding Solutions Department & Appoints New Director
Ascendis, a firm of chartered accountants in Manchester, have announced the opening of their new funding solution department and the appointment of Glyn Jones as Funding Director. In his early career, Glyn Jones worked at HSBC in the Investment Transactions team and also worked in sales for a period of time until 2011, when he moved into finance. Since then, Glyn has been helping SMEs with their cash flow requirements and his